of follow-up is two years and the primary endpoint was major adverse cardiovascular events (MACE), including all-cause death, non-fatal myocardial infarction and target vessel revascularization (TVR).
CONCLUSIONS Hypothyroidism is associated with cardiac markers and damaged cardiac function in STEMI. In two-year follow-up, hypothyroidism is a predictor for MACE and TVR in STEMI patients treated with primary PCI. Further studies on treatment of MI with thyroid dysfunction are needed BACKGROUND Triple antiplatelet therapy (TAT) including cilostazol has showed beneficial effect on mortality with safety in patients with ST elevation myocardial infarction (STEMI) compared to dual antiplatelet therapy (DAT). However, considering the bleeding risk in elderly patients, it is not clear whether these beneficial effects also show or not. Thus, we compared the effect of triple antiplatelet therapy (TAT) with DAT in elderly patients with STEMI underwent primary percutaneous coronary intervention (PCI).
METHODS From 2007 to 2014, a total of 1401 consecutive patients (79.6% male) with STEMI underwent primary PCI were analyzed retrospectively. Patients were divided into two groups according to their age (group 1: < 75 years old, group 2: !75 years old). Primary endpoint was all-cause mortality during follow-up period.
RESULTS
Of the 1401 patients, there were 1160 (82.8%, mean age 56.3AE10.4) patients in group 1, 241 (17.2%, 80.3AE4.5) patients in group 2. Prevalence of DM, hypertension and multi-vessel disease were more common in group 2. In group 1, there were 235 patients (20.3%) with TAT and 29 patients (12.0%) with TAT in group 2. Over a mean follow-up period of 2.1AE1.5 years, there were 90 in deaths (4.3% in group 1 vs. 28.3% in group 2). Kaplan-Meier survival analysis revealed that TAT was associated with lower mortality rate in group 1 (log rank p-value¼0.023). Whereas, this beneficial effect was not noted in group 2 (log rank p-value¼0.958).
CONCLUSIONS On the contrary to young patients (< 75 years old), TAT was not associated survival benefit compared to DAT in elderly patients (!75 years old) with STEMI underwent primary PCI. 
